1.EVALUATION OF SITAGLIPTIN AND CILASTAZOL AND THEIR COMBINATION THERAPY IN STREPTOZOTOCIN INDUCED DIABETIC CARDIOMYOPATHY IN RATS Charanjeet Singh, Anil K Gupta, Manish Gupta,
Diabetic cardiomyopathy are major causes of morbidity and mortality in diabetic patients. Type 2DM patients are frequently used the combination of antidiabetic drugs but dual and triple therapy did not report to reduce cardiovascular risk significantly. There is a need of new therapeutic interventions. In present study, Type2DM induced by Nicotinamide-Streptozotocin. On 15th day, drug therapy started for 6 weeks with (i) cilastazol (100 mg/kg, b.d.) (ii) sitagliptin (100 mg/kg, o.d.), (iii) cilastazol(100mg/kg) + sitagliptin (100mg/kg,o.d.). Good glycemic control with sitagliptin (344±8.15 to 101±2.91**mg/dl, p≥0.01) and cilastazol+sitagliptin (358±4.06 to 96±2.55***, p≤0.001) except Cilastazol (326±5.0 to 152±8.0* mg/dl, p≤0.05). Combination of cilastazol and sitagliptin increased serum albumin (0.714±0.036g/dl to 1.82±0.04g/dl**, p≤0.001), decrease serum myoglobin(0.076±0.036g/dl to 0.039±0.0001g/dl**,p≤0.01), extremely significant decrease serum protein(13.18±0.036g/dl to 7.22±5.57***g/dl,p≤0.001), decrease protein in urine (2.68±0.036g/dl to 0.72±0.024***, p≤0.001) and decrease albumin in urine (0.2±0.036g/dl to 0.085±0.003 ***,p≤0.01) and decrease urine myoglobin (0.016±0.036g/dl to 0.0025±0.0001g/dl***,p≤0.001) No Body weight increase in with sitagliptin and cilastazol and combination. Histopathological features were preserved with sitagliptin and cilasazol combination therapy. Combination of cilastazol and sitagliptin improves glycemic control, retards diabetic cardiomyopathy markers and does not increase body weight; decrease more detrimental inflammatory markers in adult streptozotocin-nicotinamide induced diabetic cardiomyopathy in rats. Combination therapy showed a synergistic effect and was promising in cardiovascular risk reduction.